Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 4, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
In episode 12 of this NeurologyLive® Peer Exchange series, "Unmet Needs in Treating Insomnia," a panel of expert physicians offer shared insight on the pharmacologic treatment landscape of insomnia, with a focus on mainstay drug classes.
Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team, including an approval for adults with insomnia, a number of treatment application acceptances for various neuromuscular disorders, and a few clinical holds placed on trials in Alzheimer and Parkinson disease.
The cognitive neurologist at the University of California, San Francisco discussed recently published data on the presence of cognitive post-acute sequelae of COVID-19, provided insight on the research needed to explain more about its pathogenesis, and the realistic possibility of developing neurocognitive disorders.
Although research illustrates the persistence of inequities between women and men in neurology, Kathleen B. Digre, MD, FAHS; Jessica Ailani, MD, FAHS, FAAN; and Irene A. Malaty, MD shared encouraging thoughts and experiences highlighting the progress made in recent years for National Women Physicians Day.
Alireza Atri, MD, PhD, discusses aducanumab’s recent FDA approval for the treatment of Alzheimer disease and the impact it has had on the landscape of care in episode 4 of this NeurologyLive® Insights series "Testing for Early Diagnosis of Alzheimer’s Disease."